Imatinib mesylate

Imatinib mesylate structural formula

CAS Number220127-57-1
Molecular FormulaC30H35N7O4S
Molecular Weight589.720
  • Imatinib mesylate
  • Methanesulfonic acid--4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide (1/1)
  • Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1)
  • 220127-57-1
  • STI571
  • Imatinib mesilate
  • Gleevec
  • Shantinib
  • UNII-8A1O1M485B
  • imatinib methansulfonate
  • imatinib monomesylate
  • imatinib methanesulfonate


Determination Imatinib Mesylate on Obelisc R Column

February 10, 2021

Separation type: Liquid Chromatography Ion Exclusion
View on

High Performance Liquid Chromatography (HPLC) Method of Imatinib mesylate.

Imatinib mesylate is effective in treating chronic myeloid leukemia and metastatic gastrointestinal stromal tumors. It is classified as a signal transduction inhibitor. It can be retained on an Obelisc R column, which has both positive and negative ion-pairs embedded in the stationary phase, allowing for the fine tuning and separation of a wide range of compounds with different ionic properties. Imatinib mesylate can be determined isocratically using a simple MS-compatible mobile phase of acetonitrile (ACN) and water with Ammonium Formate (AmFm) buffer and detected by UV at 270nm, ELSD, CAD or LC/MS.


Column Obelisc R, 4.6×150 mm, 5 µm, 100A
Mobile Phase MeCN -50%
Buffer Ammonium Formate pH 3.0 – 50 mM
Flow Rate 1.0 ml/min
Detection UV 270nm



Class of Compounds
Analyzing Compounds Imatinib Mesylate


Application Column

Obelisc R

SIELC has developed the Obelisc™ columns, which are mixed-mode and utilize Liquid Separation Cell technology (LiSC™). These cost-effective columns are the first of their kind to be commercially available and can replace multiple HPLC columns, including reversed-phase (RP), AQ-type reversed-phase, polar-embedded group RP columns, normal-phase, cation-exchange, anion-exchange, ion-exclusion, and HILIC (Hydrophilic Interaction Liquid Chromatography) columns. By controlling just three orthogonal method parameters - buffer concentration, buffer pH, and organic modifier concentration - users can adjust the column properties with pinpoint precision to separate complex mixtures.

Select options
Application Analytes:
Imatinib mesylate
SIELC Technologies usually develops more than one method for each compound. Therefore, this particular method may not be the best available method from our portfolio for your specific application. Before you decide to implement this method in your research, please send us an email to so we can ensure you get optimal results for your compound/s of interest.

Separation of Imatinib mesylate on Newcrom R1 HPLC column

May 16, 2018
Separation of Imatinib mesylate on Newcrom R1 HPLC column

Imatinib mesylate can be analyzed by this reverse phase (RP) HPLC method with simple conditions. The mobile phase contains an acetonitrile (MeCN), water, and phosphoric acid. For Mass-Spec (MS) compatible applications the phosphoric acid needs to be replaced with formic acid. Smaller 3 µm particles columns available for fast UPLC applications. This liquid chromatography method is scalable and can be used for isolation impurities in preparative separation. It also suitable for pharmacokinetics.

Application Column

Newcrom R1

The Newcrom columns are a family of reverse-phase-based columns. Newcrom A, AH, B, and BH are all mixed-mode columns with either positive or negative ion-pairing groups attached to either short (25 Å) or long (100 Å) ligand chains. Newcrom R1 is a special reverse-phase column with low silanol activity.

Select options
Application Analytes:
Imatinib mesylate
The result was obtained by a proprietary SIELC algorithm. It may deviate from the actual experimental data. The experimental data are available upon request. Contact us by e-mail: or by phone: 847-229-2629.